Wrapping as a Biomarker in Personalized Drug Therapy

It is seldom the case that idiosyncratic or disease-related genomic differences would translate as significant structural changes in the gene products. The functional demands of the wild-type locus cannot generally be compromised without a 

Fernandez, Transformative Concepts for Drug Design Target Wrapping, 211 

In other words, a single amino acid substitution can turn a wrapping residue into a bad wrapper (that is, one of the following amino acids G, A, N, D, S, T, or P) and hence generate a dehydron in lieu of the well-wrapped hydrogen bond in the wild type. Thus, a mutation can produce a new dehydron, actually an idiosyncratic dehydron, which in turn may be wrapped intermolecularly by a purposely designed drug, as shown schematically in Fig. 13.1. 

---